First patients enrolled in the sWITCH-VO trial

On 21 October 2026, the first patient was successfully enrolled in the sWITCH-VO trial at the lead site, Regensburg Academic Medical Centre. Cologne Academic Medical Centre followed as the second lead site and was also able to enrol a patient on 30 October. The conditions for further recruitment are now in place: since the beginning of November, 12 of the 13 study centres have already received the greenlight and can begin enrolling patients.

The sWITCH-VO team is looking forward to the cross-site recruitment that is now getting underway and to continued successful collaboration with all participating study centres!

sWITCH-VO is investigating whether, in cases of spondylodiscitis – a predominantly bacterial inflammation affecting both the intervertebral disc (discitis) and the adjacent vertebral bodies (spondylitis) – an early switch from intravenous to oral antibiotic therapy (tablets) after just 7 days, rather than the usual 14, is just as effective and safe.